Fosun International Limited · HKEX:656
Fosun International — H1 2025 Earnings Presentation
52 slides from Fosun International's earnings presentation, Aug 29, 2025
Slide 1: From Shared Vision to Greater Horizons
From Shared Vision to Greater Horizons Fosun International 2025 Interim Results 2025-08-29 | Shanghai
Slide 2: Disclaimer
Disclaimer This document is not intended to provide a full explanation of any relevant matters of Fosun International Limited (“Fosun” or the “Company”). You must refrain from relying on any information set out in this document. No statement, guarantee or undertaking is or will be made or given at p
Slide 3: Table of Contents
Table of Contents 01. Financials 02. Business 03. Strategic Development 3
Slide 4: 2025H1 Financials: Notable Increase in Overseas Revenue Share with Robust Fundamental Business
2025H1 Financials: Notable Increase in Overseas Revenue Share with Robust Fundamental Business 1. Financials 2. Business 3. Strategic Development Total Revenue Overseas Revenue Industrial Operating Profit2 Profit Attributable to Owners of the Parent 87.3 46.67 3.15 0.66 Billion/RMB Billion/RMB Billi
Slide 5: 2025H1 Financials: Stable Business Fundamental, Revenue Structure Continues to Optimize
2025H1 Financials: Stable Business Fundamental, Revenue Structure Continues to Optimize 1. Financials 2. Business 3. Strategic Development Surging Biotech Propels 15% Solid Growth with Great 30% Core Business Growth Overseas Potential 10% Health Wealth Revenue (Billion/RMB) Revenue (Billion/RMB) 61%
Slide 6: 2025H1 Financials: Core Subsidiaries Consolidating Industrial Foundation
2025H1 Financials: 4 Core Subsidiaries Consolidating Industrial Foundation 1. Financials 2. Business 3. Strategic Development 4 Core Subsidiaries Fosun Pharma Yuyuan Billion/RMB Billion/RMB -4.7% YOY -30.7% YOY 20.38 19.42 27.57 19.11 Fosun Pharma 22% Yuyuan 28% 2024H1 2025H1 2024H1 2025H1 Fosun Tou
Slide 7: 2025H1 Financials: Broadening Financing Channels, Declining Borrowing Cost
2025H1 Financials: Broadening Financing Channels, Declining Borrowing Cost 1. Financials 2. Business 3. Strategic Development Public Markets Financing 1 Cash, Bank Balances and Term Average Cost of Borrowings Deposits 13.62 Billion/RMB 67.83 Billion/RMB 5.3% (excl. consolidated subsidiaries) Exclu
Slide 8: 2025H1 Financials: Stable Credit Rating, Successful Issuance of USD Bonds
2025H1 Financials: Stable Credit Rating, Successful Issuance of USD Bonds 1. Financials 2. Business 3. Strategic Development S&P Global Ratings Report The Group’s Credit Indicators Continued to Improve • Positive Rating: On May 30, 2024, S&P Global Ratings affirmed Fosun International’s “BB-” rating
Slide 9: Evolving Finance Strategy to Navigate the Group through Economic Cycle
Evolving Finance Strategy to Navigate the Group through Economic Cycle 1. Financials 2. Business 3. Strategic Development Strategic Focus, Steady Development 2025: Finance strategy to persist • Further focused on strategic core businesses with market leadership position • For four consecutive years,
Slide 10: Global Operations with Enhanced Quality and Efficiency, Growth Driven by Technology Innovation
1 Global Operations with Enhanced Quality and Efficiency, Growth Driven by Technology Innovation 1. Financials 2. Business 3. Strategic Development Globalization with Enhanced Quality and Efficiency Growth Driven by Technology Innovation Continued Pharmaceutical Overseas Expansion Innovation-driven
Slide 11: Progressive Asset Revaluation, Ongoing Debt Deduction Commitment
2 Progressive Asset Revaluation, Ongoing Debt Deduction Commitment 1. Financials 2. Business 3. Strategic Development Asset: Progressive Revaluation Liability: Stable Debt Level with Reduced Cost The financial strategy centered on balance sheet optimization through non-core asset Secondary Market1 d
Slide 12: Diversified Financing Channels, Declining Cost of Borrowings
3 Diversified Financing Channels, Declining Cost of Borrowings 1. Financials 2. Business 3. Strategic Development Diversified Financing Channels Declining Cost of Borrowings 境 • 虽然境内公开债券市场对于民营企业挑战重重，但 Bank Financing: Solid Domestic Base, Continued Overseas Expansion Bond Financing Costs • Building o
Slide 13: Outstanding Asset-light Operating Capability Empowering Insurance Investment
4 Outstanding Asset-light Operating Capability Empowering Insurance Investment 1. Financials 2. Business 3. Strategic Development Outstanding Asset-light Operating Capability Empowering Insurance Investment • Building on the strong growth of its high-quality insurance business and the Tourism: As of
Slide 14: Finance Strategy Paves a Promising Future
Finance Strategy Paves a Promising Future 1. Financials 2. Business 3. Strategic Development Unswervingly prioritizing the Group's portfolio, focusing resources on cultivating businesses with the potential to become industry leader Continuously advancing the implementation of asset-light strategies,
Slide 15: Table of Contents
Table of Contents 01. Financials 02. Business 03. Strategic Development 15
Slide 16: Health
Slide 17: Health Segment Business Highlights
Health Segment Business Highlights 1. Financials 2.Business 2.1Health 3.Strategic Development 1H25 Total Revenue Fosun Pharma Henlius 30% 19.43 2.82 Health 61% 22.57 v Billion/RMB Revenue ◼ ◼ v to grow +14.26%YoY Billion/RMB Innovative Drugs revenue continued Net cash flow generated from ◼ ◼ Revenue
Slide 18: Fosun Pharma's Key Innovative Products Grow Steadily
Fosun Pharma’s Key Innovative Products Grow Steadily 1. Financials 2.Business 2.1Health 3.Strategic Development Revenue Net Profit Attributable to Shareholders Innovative Drugs Revenue Billion/RMB Billion/RMB • Steady growth, exceeding RMB 4.3 billion (+14.3%) Pharama Med Tech Healthcare 3.13 3.66 2
Slide 19: Business Highlights – Sustainable and Innovative Product Pipelines
Business Highlights – Sustainable and Innovative Product Pipelines 1. Financials 2.Business 2.1Health 3.Strategic Development • In the first half of 2025, in terms of therapeutic drugs, 4 Innovative Drugs with a total of 5 indications independently developed and licensed- in by the Group were approv
Slide 20: Business Highlights - Licensing & Global Operations
Business Highlights - Licensing & Global Operations 1. Financials 2.Business 2.1Health 3.Strategic Development • Under the industry background of VBP and NRDL negotiation, both generic drugs and innovative drugs are facing price challenges • Continuing to implement the international strategy across
Slide 21: Evolution of the Medical Service & Healthcare Management Model
Evolution of the Medical Service & Healthcare Management Model 1. Financials 2.Business 2.1Health 3.Strategic Development Focus on Premium Medical Care and Professional Services Expansion and Optimization of Eco-models Focusing on rich young women and middle-aged to elderly groups, combine insurance
Slide 22: Medical Devices & Diagnostics Brands
Medical Devices & Diagnostics Brands 1. Financials 2.Business 2.1Health 3.Strategic Development Aesthetic Medical Professional Medical Device Fosun Diagnostics The world’s leading energy-based aesthetic medical devices Intuitive Surgical is a global leader in surgical robotics ✓ In August, Fosun Dia
Slide 23: Digitalization and AI-Driven Business Growth
Digitalization and AI-Driven Business Growth 1. Financials 2.Business 2.1Health 3.Strategic Development • Digitalization and AI strategic deployment: gradually covering R&D, operations and product applications. Fosun Pharma is among the first domestic pharmaceutical enterprises to deploy large langu
Slide 24: Happiness
IR OK Happiness
Slide 25: Happiness Segment Business Highlights
Happiness Segment Business Highlights 1.Financials 2.Business 2.2 Happiness 3. Strategic Development 2025H1 Total Revenue Yuyuan Fosun Tourism Group (FTG) 29% Happiness 33.72 Billion/RMB Revenue: 19.11 Billion/RMB Revenue: 9.53 Billion/RMB ◼ Revenue decreased by 21.9% yoy, mainly ◼ The industry rema
Slide 26: Yuyuan: Quarter-on-Quarter Improvement in Core Operations, Strong Cash Reserves
Yuyuan:Quarter-on-Quarter Improvement in Core Operations, Strong Cash Reserves 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Operating Revenue Gross Profit Operating Revenue Unit: 100 Million/RMB Unit: 100 Million/RMB • The operating revenue reached RMB 19.11 billion, down by 31%
Slide 27: Yuyuan: Q2 Recovery in Jewelry & Fashion, Growth in Core Products of Liquor Business and Emerging E-commerce
Yuyuan: Q2 Recovery in Jewelry & Fashion, Growth in Core Products of Liquor Business and Emerging E-commerce 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Q2 Recovery in Jewelry & Fashion Gross Profit of Jewelry & Fashion Jewelry & Fashion Unit: 100 Million/RMB • The Fashion Jewel
Slide 28: Yuyuan Tourist Mart: Initial Results of Renovation
Yuyuan Tourist Mart: Initial Results of Renovation 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Occupancy Rate Sales Volume Visitor Traffic Number of Events 99% 2.61 Billion/RMB ～19 Million +1,000 Up by 8 pct yoy Up by 55% yoy Remain Flat Up by 7% yoy 1 Self-owned IP & Super-scen
Slide 29: FTG: Record-High Revenue with Robust Profit Growth
FTG: Record-High Revenue with Robust Profit Growth 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Business Volume of Tourism Operation1 Revenue Unit: 100 Million/RMB Unit: 100 Million/RMB 106.7 95.3 +2%2 102.3 94.1 +1% 6.0 Thanks to continued improvement in 100.7 102.3 FTG’s global
Slide 30: Global Operations: Club Med Achieves New Milestones with Improved Efficiency
Global Operations: Club Med Achieves New Milestones with Improved Efficiency 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Business volume1 hit a new high with growth across three key regions Average daily bed rate1 continued to rise, reflecting brand value Double-digit growth in
Slide 31: Operations in China: Strengthening Core Business, Pursuing Asset-light Strategy, Embracing AI
Operations in China: Strengthening Core Business, Pursuing Asset- light Strategy, Embracing AI 1. Financials 2. Business 2.2 Happiness 3. Strategic Development Asset-light Strategy Progressing Steadily Taicang Alps Phase II officially commenced, aiming to create a world-class winter resort landmark
Slide 32: Wealth
Slide 33: Wealth Segment Business Highlights
Wealth Segment Business Highlights 1. Financials 2. Business 2.3 Wealth 3. Strategic Development 2025H1 Total Revenue Fosun Insurance Portugal Peak Re 15% Total Premium Revenue 27.83 Billion/RMB 10% 3.27 Billion/EUR Total Premium Revenue 1.06 Billion/USD Maintaining the top market share in ◼ Revenue
Slide 34: Insurance Business Highlights
Insurance Business Highlights 1. Financials 2. Business 2.3 Wealth 3. Strategic Development Global Footprints Overseas Insurers: Efficient operations become cornerstone of profits 2025H1 Premium Scale: 42.4 Billion/RMB Steadily expand the business scale, Prudently manage risk exposure, with excellen
Slide 35: Asset Management (Investment) Business Layout
Asset Management (Investment) Business Layout 1. Financials 2. Business 2.3 Wealth 3. Strategic Development Global Footprints for Asset Management Platforms Investments in 25H1 Major Existing Investments 2025H1 AUM1 1,197.3 Billion/RMB Chagee HAFS 4 portfolio companies filed for IPOs European Asset
Slide 36: Intelligent Manufacturing
Slide 37: Intelligent Manufacturing Segment Business Highlights
Intelligent Manufacturing Segment Business Highlights 1. Financials 2. Business 2.4 Intelligent Manufacturing 3. Strategic Development 2025H1 Total Revenue Hainan Mining Revenue: 2.415 Billion/RMB 41% 4.02 Billion/RMB Up by 10.46% yoy Intelligent Manufacturing ■ Revenue decreased by 24.6% yoy, prima
Slide 38: Hainan Mining: Focus on Resources to Continuously Build Resilience Through Market Cycles
Hainan Mining: Focus on Resources to Continuously Build Resilience Through Market Cycles 1. Financials 2. Business 2.4 Intelligent Manufacturing 3. Strategic Development Downturn Cycle, Steady Performance Stable Iron Ore Output, Oil and Gas Output Up by Over 50% Average Platts 62% Fe Iron Ore Index
Slide 39: Wansheng: The World's Leading New Functional Materials Enterprise
Wansheng: The World’s Leading New Functional Materials Enterprise 1. Financials 2. Business 2.4 Intelligent Manufacturing 3. Strategic Development Enhancing operational capability through supply and sales synergy Focusing on base development with accelerated construction Sales Revenue (100 Million/R
Slide 40: Table of Contents
Table of Contents 01. Financials 02. Business 03. Strategic Development 40
Slide 41: Strategy Review: Navigating Economic Cycles with Long-term Vision and Business Streamlining
Strategy Review: Navigating Economic Cycles with Long-term Vision and Business Streamlining 1. Financials 2. Business 3. Strategic Development 3.2 Strategy Review Fosun: Three Decades of Strategic Industry Evolution Phase I: Phase II: Phase III: Phase IV: Phase V: Founding and Domestic Global Deepen
Slide 42: Strategic Framework: Aligning Forces, Building Consensus
Strategic Framework: Aligning Forces, Building Consensus 1. Financials 2. Business 3. Strategic Development 3.2 Strategic Framework Strategic Positioning A Global Innovation-Driven Consumer Group Mission & Creating happier lives for families worldwide. Rooted in China, Vision creating a global happi
Slide 43: Global Operations: Combining Global Resources with China's Capabilities
Global Operations: Combining Global Resources with China’s Capabilities 1. Financials 2. Business 3. Strategic Development 3.3 Business Alignment Global R&D and Business Development Chinese Culture Goes Global • In August 2025, license out a small-molecule orally administered DPP-1 inhibitor oversea
Slide 44: Flywheel Model: Outstanding Asset-light Operating Capability Empowers Mutual Growth in Insurance
Flywheel Model: Outstanding Asset-light Operating Capability Empowers Mutual Growth in Insurance 1. Financials 2. Business 3. Strategic Development 3.3 Business Alignment • Aging Population Growing insurance demand is accelerating the accumulation of investable funds Investment+ Insurance • Rising h
Slide 45: Marketing Force: Value Marketing System, and Strengthen Empowerment of Marketing Management
Marketing Force: Value Marketing System, and Strengthen Empowerment of Marketing Management 1. Financials 2. Business 3. Strategic Development 3.3 Business Alignment Customer Marketing Product Comprehensive Core Product Defies Size Opportunities of In- Fosun Insurance Strong Business Backed by Fosun
Slide 46: AI Applications: Drive Full-chain Implementation Across All Industries
AI Applications: Drive Full-chain Implementation Across All Industries 1. Financials 2. Business 3. Strategic Development 3.3 Business Alignment R&D Production Supply Sale Service Operating Capabilities Fully Embrace and Implement AI AI in Drug Discovery AI-powered Market Healthcare Services Health
Slide 47: Organizational Support: Create and Share Incremental Value While Upholding Entrepreneurial Spirit
Organizational Support: Create and Share Incremental Value While Upholding Entrepreneurial Spirit 1. Financials 2. Business 3. Strategic Development 3.4 Organizational Support Strengthen organizational support for business alignment Build a Fluid Organization – Flexible Management, Choosing What Wor
Slide 48: Committed to Global Services, Advancing Corporate Sustainable Development
Committed to Global Services, Advancing Corporate Sustainable Development 1. Financials 2. Business 3. Strategic Development 3.5 ESG E S G Rural Doctors Program Corporate Governance Carbon Neutrality A total of 429 volunteers have been sent • Continuous optimization/evolution of ERM Target by 2050 t
Slide 49: Excellent ESG Performance with Recognition Worldwide
Excellent ESG Performance with Recognition Worldwide 1. Financials 2. Business 3. Strategic Development 3.5 ESG • MSCI ESG rating maintained at AA for four consecutive ESG Rating years Related Associations1 • Selected as a constituent of the MSCI CHINA ESG LEADERS 10-40 Index • MSCI ESG rating of Su
Slide 50: Appendix
FOSUN 8&2 Appendix FOSUN 1 will ali sat Mas fh aeitBhieAuis.. : 50
Slide 51: Top Secondary Holdings
Top 20 Secondary Holdings1 As of June 30, 2025 No. Stock Name % Held2 Market Value (Billion/RMB) Market Value (Billion/USD) 1 Fosun Pharma (A+H)3 36.23% 23.52 3.29 2 BCP 20.03% 16.81 2.35 3 Yuyuan3 61.84% 13.37 1.87 4 Hainan Mining3 47.48% 6.88 0.96 5 Wansheng3 29.56% 1.73 0.24 6 CHAGEE 4.01% 1.38 0
Slide 52: Fosun International 2025 Interim Results
Fosun International 2025 Interim Results https://www.fosun.com https://ir.fosun.com Fosun WeChat Fosun IR WeChat Fosun Weibo Fosun Video Fosun Douyin Official Account Official Account Channel